Jasper Therapeutics Reports Q3 Results with Significant Net Loss Due to Acquisition Costs

Jasper Therapeutics (JSPR) reported third-quarter financial results characterized by a substantial net loss of $144.5 million, compared to a loss of $18.7 million in the prior year. The widened deficit was primarily driven by a $129.5 million expense related to acquired in-process R&D following the acquisition of Kira Pharmaceuticals. Despite the heavy net loss, the company saw a significant reduction in diluted loss per share to $10.19 from $32.08 year-over-year. Revenue for the quarter reached $8,000, up from zero in the previous period. The company's liquidity position improved significantly, with cash and cash equivalents rising to $135.3 million as of September 30, 2026.

By https://seekingalpha.com/user/51785401/bio · Seeking Alpha ·

Jasper Therapeutics Reports Q3 Results with Significant Net Loss Due to Acquisition Costs

Tickers: $JSPR

Topics: acquisition earnings net loss R&D expenses revenue reverse stock split

Read the full article at Seeking Alpha

Part of the story Next Hydrogen Solutions Reports Q3 Net Loss of $6.46 Million and Declining Revenue (2 articles)

More World news